Capricor Therap (CAPR) Stock Price, Quote & News

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1755

Website: www.capricor.com

Address:

10865 Road to the Cure, Suite 150, San Diego, United States

LouMaglie Feb. 6 at 4:13 AM

$CAPR I just looked at my 2026 trades for $CAPR and I am glad I added 385 total shares. I am happy to be a part of this community. Good people. Great Cause. Go Linda

0 · Reply

HamBoneXoXo Feb. 6 at 3:51 AM

$CAPR Sunday school 8:30 am - 9:30 am Topic: How to make any desired P for lvef in a total population of 106? Subsampled I; with n = 83; p = 0.041 Subsampled II; with n = 64; P = 0.017

0 · Reply

viber7 Feb. 6 at 2:39 AM

$CAPR Look at slide 26, right panel. Cardiomyopathy patients--120% slowing, Dera vs placebo. p = 0.017. @Hambone take note, with your crazy preoccupation with p of 0.05.

1 · Reply

viber7 Feb. 6 at 2:25 AM

$CAPR Stupid repetitive word salad. Stupid to the nth power where n is the number of times you cling to stupidity and have been refuted by smart people.

1 · Reply

viber7 Feb. 6 at 2:20 AM

$CAPR Cryptos are crap abstractions. Even OTC spec stocks have some tangible value.

0 · Reply

allscienceandmoney Feb. 6 at 2:19 AM

$CAPR FDA approved a drug that failed its primary endpoint. p = 0.97. By any conventional standard, the trial failed. They approved it anyway. Qalsody (tofersen) for SOD1-ALS received accelerated approval in 2023 after missing its functional endpoint. The advisory committee voted 9-0 that the biomarker reduction was “reasonably likely to predict benefit”, then 3-5 against “convincing evidence of effectiveness.” From a strict frequentist lens, this looks indefensible. From a calibrated Bayesian lens, it’s defensible, and arguably correct. FDA wasn’t asking whether the trial “worked.” They were asking which mistake causes more harm: approving under uncertainty, or withholding in a fatal disease with no alternatives. 2023 vs 2025 FDA

1 · Reply

WBinthehouse Feb. 6 at 2:03 AM

$SRPT someone was asking if Medicaid is the reason why the huge ticker drop here. Answer NO! Medicaid programs are required to cover most FDA approved drugs, including high-cost specialty and gene therapies, under federal rules with rebates via the Medicaid Drug Rebate Program. There is no broad federal “cut” eliminating coverage for expensive drugs like these. Might be the obvious that we’ve all been talking about all these months. Just gonna leave it here. This ticker has been already trashed. Don’t know but one more bad news it’ll go single digits quick. Will make analyst from HCW as prophetic. $CAPR

1 · Reply

hegdaom Feb. 6 at 1:31 AM

$CAPR

0 · Reply

Machman1 Feb. 6 at 12:57 AM

$CAPR new slide show states 250 fte. Believe we were at 200 in the fall. Company is hiring ramping up for launch

0 · Reply

Cl92 Feb. 6 at 12:50 AM

$CAPR massive rotation into Bio would be cool…

0 · Reply

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript

Dec 7, 2025, 8:21 AM EST - 2 months ago

Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel

Dec 6, 2025, 1:18 AM EST - 2 months ago

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript

Dec 4, 2025, 4:01 PM EST - 2 months ago

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Dec 3, 2025, 2:21 PM EST - 2 months ago

Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say

Dec 3, 2025, 9:23 AM EST - 2 months ago

Capricor Therapeutics Duchenne Treatment Shows Strong Heart And Muscle Results In Trial

Dec 3, 2025, 7:44 AM EST - 2 months ago

Capricor's muscle disorder cell therapy succeeds in late-stage study

Nov 24, 2025, 1:49 PM EST - 2 months ago

Martin Shkreli Takes Aim At Capricor — Stock Sinks

Nov 10, 2025, 11:21 PM EST - 3 months ago

Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 9:15 AM EST - 3 months ago

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

Oct 31, 2025, 9:15 AM EDT - 3 months ago

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Oct 3, 2025, 10:45 AM EDT - 4 months ago

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Sep 29, 2025, 3:51 PM EDT - 4 months ago

Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026

Sep 29, 2025, 9:08 AM EDT - 4 months ago

Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway

Sep 25, 2025, 11:07 AM EDT - 4 months ago

Capricor Therapeutics, Inc. - Special Call

Sep 25, 2025, 7:15 AM EDT - 4 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

Sep 13, 2025, 11:35 AM EDT - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Sep 9, 2025, 9:20 AM EDT - 5 months ago

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

Aug 28, 2025, 7:05 PM EDT - 5 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 22, 2025, 10:20 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 18, 2025, 11:35 AM EDT - 6 months ago

Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Conference Call Transcript

Aug 8, 2025, 8:30 AM EDT - 6 months ago

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Aug 6, 2025, 9:00 AM EDT - 6 months ago

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Jul 31, 2025, 8:45 AM EDT - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit - CAPR

Jul 30, 2025, 4:27 PM EDT - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit – CAPR

Jul 30, 2025, 11:07 AM EDT - 6 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

SRPT CABA NGNE NTLA QURE RCKT

Jul 17, 2025, 4:46 PM EDT - 7 months ago

BREAKING: Capricor Therapeutics Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses

Jul 16, 2025, 7:55 PM EDT - 7 months ago

Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm

Jul 14, 2025, 4:14 PM EDT - 7 months ago

Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors

Jul 14, 2025, 7:43 AM EDT - 7 months ago

Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter

LouMaglie Feb. 6 at 4:13 AM

$CAPR I just looked at my 2026 trades for $CAPR and I am glad I added 385 total shares. I am happy to be a part of this community. Good people. Great Cause. Go Linda

0 · Reply

HamBoneXoXo Feb. 6 at 3:51 AM

$CAPR Sunday school 8:30 am - 9:30 am Topic: How to make any desired P for lvef in a total population of 106? Subsampled I; with n = 83; p = 0.041 Subsampled II; with n = 64; P = 0.017

0 · Reply

viber7 Feb. 6 at 2:39 AM

$CAPR Look at slide 26, right panel. Cardiomyopathy patients--120% slowing, Dera vs placebo. p = 0.017. @Hambone take note, with your crazy preoccupation with p of 0.05.

1 · Reply

viber7 Feb. 6 at 2:25 AM

$CAPR Stupid repetitive word salad. Stupid to the nth power where n is the number of times you cling to stupidity and have been refuted by smart people.

1 · Reply

viber7 Feb. 6 at 2:20 AM

$CAPR Cryptos are crap abstractions. Even OTC spec stocks have some tangible value.

0 · Reply

allscienceandmoney Feb. 6 at 2:19 AM

1 · Reply

WBinthehouse Feb. 6 at 2:03 AM

1 · Reply

hegdaom Feb. 6 at 1:31 AM

$CAPR

0 · Reply

Machman1 Feb. 6 at 12:57 AM

$CAPR new slide show states 250 fte. Believe we were at 200 in the fall. Company is hiring ramping up for launch

0 · Reply

Cl92 Feb. 6 at 12:50 AM

$CAPR massive rotation into Bio would be cool…

0 · Reply

Bentradez Feb. 6 at 12:09 AM

$CAPR AI works well as an objective voice so you can help avoid your bullish/bearish biases. I asked what value CAPR should be valued at today based on cash on hand, and its pipeline. ChatGPT- ~$60 per share Grok- $40-$55 per share Gemini- $47-$67 per share With these big numbers for todays value, I asked each one about why there is such a big disconnect between the stock price today and what it should be valued at. Read the comments for the general consensus from them

1 · Reply

wkee Feb. 5 at 11:44 PM

$CAPR made a deposit in Capr today !!

0 · Reply

BillionerOfKing Feb. 5 at 11:07 PM

$CAPR Current Stock Price: $23.03 Contracts to trade: $23.0 CAPR Feb 20 2026 Call Entry: $0.70 Exit: $1.29 ROI: 85% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

patatechaude Feb. 5 at 10:37 PM

$CAPR Know what you own. $23 will look stupidly cheap in 12 months... $XBI

1 · Reply

Fenderstrat68 Feb. 5 at 9:59 PM

$CAPR with 1.2mil shares traded, I m wondering who is selling? Pretty sure most on here are buying, or wish they could. Crazy to think someone is giving up so close to the finish line!

2 · Reply

ignoreo Feb. 5 at 9:55 PM

i never touched these but the sequence is comedy gold for convicted conman/felon and de facto murderer martin shkreli 1) shorts quantum ($IONQ/$RGTI) for years, calls it zero. stocks rip over 500% on him 2) takes a break from getting fckd on quantum, tries to make it big on $CAPR. sends his liquid net worth to ~$0 3) takes bribe from joshua silverman, flips long quantum, pumps $QCLS at peak quantum hype. no one buys his BS 4) entire quantum bubble craters immediately after he flips long

1 · Reply

Captenotwo Feb. 5 at 9:47 PM

$CAPR I think I bought 500 3 times today. I dont want to look. I know my last order for 22.85 went through. I know I placed others that were filled. This is ridiculous. Hold till approval. Cap.

2 · Reply

hegdaom Feb. 5 at 9:32 PM

$CAPR Waiting game for BLA & Phase 3 full data. LFG

0 · Reply

hegdaom Feb. 5 at 9:14 PM

$CAPR

0 · Reply